Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)
China flag China · Delayed Price · Currency is CNY
32.20
+0.72 (2.29%)
At close: Feb 6, 2026

SHE:002422 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
Operating Revenue
17,59521,10720,71418,60116,93616,128
Other Revenue
705.65705.65739.64437.62341.23336.6
18,30021,81221,45419,03817,27716,464
Revenue Growth (YoY)
-18.66%1.67%12.69%10.19%4.94%-6.65%
Cost of Revenue
9,55810,61310,2919,0847,9937,866
Gross Profit
8,74211,20011,1639,9549,2848,598
Selling, General & Admin
4,2874,8015,5925,6575,8775,608
Research & Development
2,2192,1711,9441,7951,7371,527
Other Operating Expenses
63.78110.88184.61192.45150.4198.76
Operating Expenses
6,6027,1567,7567,6947,8007,377
Operating Income
2,1404,0443,4072,2601,4841,221
Interest Expense
-111.78-151.62-361.54-475.22-518.34-554.86
Interest & Investment Income
300.58416.62462.47278.81244.03125.2
Currency Exchange Gain (Loss)
16.8916.8933.36-41.86-2.31-46.12
Other Non Operating Income (Expenses)
-97.11-44.08-18.95-143.9-21.84-31.17
EBT Excluding Unusual Items
2,2494,2823,5221,8781,186713.63
Gain (Loss) on Sale of Investments
27.6419.914.679.864.830.42
Gain (Loss) on Sale of Assets
5.670.812.635.4-7.94-20.04
Asset Writedown
-102.23-65.85-58.62-1.93-13.2-11.24
Other Unusual Items
48.7448.7499.621778.38272.26
Pretax Income
2,2294,2853,5802,0681,178955.03
Income Tax Expense
542.91923.4933.79363.7309.5163.55
Earnings From Continuing Operations
1,6863,3622,6471,704868.12791.48
Minority Interest in Earnings
-20.09-426.06-190.531.1234.4437.91
Net Income
1,6662,9362,4561,7051,103829.39
Net Income to Common
1,6662,9362,4561,7051,103829.39
Net Income Growth
-43.80%19.53%44.03%54.67%32.94%-11.57%
Shares Outstanding (Basic)
1,5991,5781,4531,3981,4141,430
Shares Outstanding (Diluted)
1,5991,5781,5451,4831,4141,430
Shares Change (YoY)
2.11%2.18%4.17%4.91%-1.15%0.06%
EPS (Basic)
1.041.861.691.220.780.58
EPS (Diluted)
1.041.861.591.150.780.58
EPS Growth
-44.96%16.98%38.26%47.44%34.48%-11.61%
Free Cash Flow
1,3462,8153,5682,2301,857988.5
Free Cash Flow Per Share
0.841.782.311.501.310.69
Dividend Per Share
0.6290.7630.8000.6160.4260.319
Dividend Growth
-40.66%-4.63%29.87%44.60%33.63%-24.99%
Gross Margin
47.77%51.35%52.03%52.29%53.74%52.22%
Operating Margin
11.70%18.54%15.88%11.87%8.59%7.41%
Profit Margin
9.10%13.46%11.45%8.96%6.38%5.04%
Free Cash Flow Margin
7.35%12.90%16.63%11.71%10.75%6.00%
EBITDA
3,3565,2484,5963,4162,6902,375
EBITDA Margin
18.34%24.06%21.42%17.94%15.57%14.43%
D&A For EBITDA
1,2161,2041,1891,1561,2061,155
EBIT
2,1404,0443,4072,2601,4841,221
EBIT Margin
11.70%18.54%15.88%11.87%8.59%7.41%
Effective Tax Rate
24.36%21.55%26.08%17.59%26.28%17.13%
Revenue as Reported
18,30021,81221,45419,03817,27716,464
Advertising Expenses
-145.44265.58129.59161.81.78
Source: S&P Global Market Intelligence. Standard template. Financial Sources.